US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma ...Middle East

TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National Cancer Institute (NCI) sponsors Senhwa's...

Hence then, the article about us nci sponsors senhwa biosciences second program ind submitted for clinical trial targeting myc aberrant lymphoma was published today ( Thursday 07/08/2025 - 09:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma )

Also on site :

• ‘Fire Country’ Announces Major Change After Season 4 Cast Shake-Up
• Nearly 14,000 Pounds of Grilled Chicken Products Recalled for a Potentially Life-Threatening Reason—What to Know
• ‘Beloved’ Woodford Reserve Bourbon Is Back Nationwide